eISSN: 2084-9869
ISSN: 1233-9687
Polish Journal of Pathology
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank
vol. 70
Original paper

Green tea extract prevents the development of nonalcoholic liver steatosis in rats fed a high-fat diet

Dominika Karolczak
Monika Seget
Joanna Bajerska
Agata Błaszczyk
Sławomira Drzymała-Czyż
Jarosław Walkowiak
Andrzej Marszałek
4, 5

Electron Microscopy Laboratory, Chair and Department of Clinical Pathomorphology, Poznan University of Medical Sciences, Poland
Institute of Human Nutrition and Dietetics, Poznañ University of Life Sciences, Poland
Department of Pediatric Gastroenterology and Metabolic Diseases, Poznan University of Medical Sciences, Poland
Department of Oncologic Pathology and Prophylaxis, Poznan University of Medical Sciences, Greater Poland Cancer Center, Poznan, Poland
Chair and Department of Clinical Pathomorphology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Poland
Pol J Pat hol 2019; 70 (4): 295-303
Online publish date: 2020/03/06
Article file
Get citation
JabRef, Mendeley
Papers, Reference Manager, RefWorks, Zotero


Obesity is one of the most widespread chronic diseases in the world. In the United States of America about one-third of the adult population is suffering from obesity [1]. The main cause of this disease is the Western diet, which is high in fat, especially animal fat [1, 2, 3]. Because of these disturbances excess fat mass is formed [4]. There is a statistically proven connection between obesity, type 2 diabetes, cardiovascular diseases, and hypertension, which all constitute metabolic syndrome. Metabolic syndrome is often characterised by chronic inflammation and hepatic steatosis, which leads to non-alcoholic fatty liver disease (NAFLD). NAFLD develops from a relatively mild form of steatosis to non-alcoholic steatohepatitis (NASH), fibrosis, and cirrhosis [5]. NAFLD is the most common chronic liver disease in developed countries. The estimated prevalence of NAFLD ranges from 10% to 25% [6]. Until now, there has been no effective treatment of NAFLD. The only way to deal with this disease is weight loss and treatment of comorbid conditions [6]. Thus, dietary strategies that prevent the development of liver steatosis or its progression to NASH are critically needed [7]. One of them is drinking green tea (GT). Green tea is made from unfermented dried leaves of the plant Camellia sinensis, so its chemical composition is different than in black or oolong tea, in which the tea leaves are allowed to oxidise [8]. Green tea is widely consumed in many regions of the world, with the majority consuming 5-8 cups of green tea beverage per day [9]. Moreover, in was proven that drinking at least five cups of GT per day may have a prophylactic effect on cardiovascular diseases [10]. Green tea contains caffeine and polyphenols commonly known as catechins. The most popular catechin found in GT is (-)-epigallocatechin-3-gallate (EGCG). Other catechins are epigallocatechin (EGC), epicatechin gallate (ECG), epicatechin (EC), and catechin [11] (Fig. 1). Experimental data suggest that GT and its catechins play a significant role in protecting against NAFLD by regulating energy homeostasis and lowering oxidative stress and inflammatory response [12]. However, the majority of presented studies (including controlled human trials) have been conducted to evaluate the effect of green tea supplementation on metabolic outcomes in patients with existing NAFLD [13]. Moreover, in some studies the protective effect of green tea or its constitutes (EGCG) against NAFLD was studied with use of relative high doses of green tea extract (Bose, Kasu, Nakamoto), which did not reflect habitual consumption of this beverage. Therefore, in our study we decided to test the hypothesis that supplementation of green tea extract (GTE) reflecting the usual consumption of green tea beverage (5-8 cups/day) may protect against development of non-alcoholic fatty liver in rats fed a high-fat diet (HF).

Material and methods

High-fat diet enriched with green tea extract GTE – animal study

Twenty-four 11-week-old male Wistar rats with initial body weights ranging from 266 g to 292 g were obtained from the Department of Toxicology of Poznan University of Medical Sciences, Poland. The animals were kept in individual cages in a temperature-controlled room at 22 ±2°C, with 55% to 60% humidity and a 12-h dark/12-h light cycle. The rats were fed a chow diet (Labofeed B) purchased from Labofeed (Feed Production Plant, Kcynia near Bydgoszcz, Poland) and with tap water ad libitum for one week before the experiment. All animals were treated in accordance with the World Health Organisation guidelines for animal care. The design of the animal study was approved by the Local Bioethical Committee on Animal Research at the Department of Animal Physiology and Biochemistry, Poznan University of Life Sciences (July 2008). After seven days of adaptation to laboratory conditions, the experimental animals were randomly divided into four groups of six animals each (two study groups and two control groups). There was no difference in body weight among the groups at the beginning of the experiment. The study groups received a HF diet (modified AIN-93G diet with added lard and sunflower oil, 30 g fat/100 g diet), enriched with 1.1% and 2.0% GTE, respectively, for a total of 56 days. The control groups were fed a HF diet alone and normal standardised diet (low-fat diet – AIN-93G), respectively, for the same period of time. The composition of the animals’ diet is described in Table I.
Each ingredient in the diet was weighed (within ±0.5% of the amount required) and mixed. The mixture was then formed into equally sized granulate and placed in a temperature and humidity-controlled room to remove moisture. The rats received water and pellets ad libitum.
The food consumption (of individual rats) was calculated each day from the difference between the daily amount of food supplied and the amount of unconsumed food. The rats’ body weights were measured every seven days using electronic scales.
At the end of the experiment (day 56), and after 16 hours of starvation, the animals were weighed and euthanised by intraperitoneal lethal dose injection of thiopental (40 mg/kg body weight).

Preparation of GTE

The GTE was prepared according to the method presented by Gramza and Regula [14] with the minor modification [15] from Japanese Sencha Fukuju Green Tea, which was available commercially (House of Tea).
The tea leaves (100 g) were ground and then boiled in double-distilled water (1000 ml), followed by stirring for 15 minutes at 70°C (the procedure was repeated three times). Collected extracts were filtered through filter paper, centrifuged (at 2700 g, for 15 min), frozen and lyophilised under a vacuum (Multi Branch Trade & Manufacturing Company “Elena”, Zelazkow, Poland). HPLC analyses of the green tea catechin content were performed on a Waters Alliance HPLC System 2695 (Milford, Mass, USA) equipped with an X-Terra RP18 5 µm column (Milford). The composition of GTE is shown in Table II.
Based on the information that the mean EGCG content of a single cup (200 ml) of tea prepared with 2 g of green tea leaves ranges between 4.62 mg and 406.4 mg, the two presently employed doses of GTE, 1.1% and 2.0%, were equivalent to human intake of five and eight cups of green tea, respectively. Moreover, GTE at these doses delivers 407.6 and 741.1 mg caffeine per kilogram of animal diet (Table II).

Liver histology

Pieces of liver were fixed in 3.6% glutaraldehyde fixative in 0.1 M Na-cacodylate buffer, pH 7.4, followed by three washes in the buffer, then post fixed for one hour in 1% OsO4, dehydrated, cleared, and infiltrated within EPON Resin. Semithin sections were stained with toluidine blue and examined with an Olympus XC50 light microscope. Ultrathin sections were stained with 2% uranyl acetate, followed by lead citrate, and examined with a JEM1011 electron microscope. Hepatic steatosis was graded as follows: 0 – no steatosis; 1 – mild (< 33% of hepatocytes affected); 2 – moderate (33-66% of hepatocytes affected); and 3 – severe (more than 66% of hepatocytes affected).

Statistical analysis

All statistical analyses were performed using Statistica 12.0 software (StatSoft Inc., Tulsa, USA). The Mann-Whitney test was used to assess differences between the studied groups. The level of significance was set at p < 0.05.


In the majority of animals studied the liver steatosis was considered as low. The greatest percentage of steatosis found during examination of sections was 40%. The percentage of hepatocytes affected by steatosis in the control group consuming a HF diet (median [1st-3rd quartile]: 25% [12-34%]) was significantly higher (p < 0.033 and p < 0.050, respectively) than in the group consuming a HF diet enriched with 2.0% of GTE (9% [3-18%]) and the control group consuming the AIN-93G diet (10% [5-18%]). No significant differences were observed for the group consuming a HF diet enriched with 1.1% of GTE, in which intermediate results were observed (15% [4-30%]).
The livers of control rats (low-fat diet) had normal structure and its parenchyma had no signs of destruction or injury. Hepatic tissue consists of hepatic cords of hepatocytes. Hepatocytes had one or two nuclei with one or more nucleoli. There was no significant steatosis in control livers. There were no signs of ballooning, which would have led to cell degradation. Only single lipid droplets were observed in the cytoplasm of a few hepatocytes (Fig. 2A).
The hepatic tissue from rats fed a high-fat diet differed significantly from control livers (rats fed AIN-93G diet). There were definitely more lipid droplets in hepatocytes that had accumulated in the cells. Lipid droplets filled most of the cytoplasm, pushing the nucleus to the cell periphery. The next step was the collapse of cells and the release of their residues outside the cell. Lipid droplets in the majority of the tissue were large and created macrovesicular steatosis (Fig. 2B); when released by the collapse of cells occupying spaces between hepatocytes that impaired the structure of liver parenchyma, there were no longer hepatic cords.
Adding 1.1% GTE to the diet caused a reduction in liver steatosis (Fig. 2C). This reduction was significant, and steatosis changed from macrovesicular to microvesicular. Only in a few hepatocytes did we find ballooning and larger lipid droplets between cells generated by disintegration of hepatocytes. The addition of 2.0% GTE into the HF diet caused even more reduction in liver steatosis (Fig. 2D). The lipid content was definitely low; if any lipid droplets existed, they were small and did not change the structure of the hepatocytes. The liver parenchyma appeared similarly to that seen in a low-fat diet, without changes or interruptions in the hepatic cord system.
The same changes were observed during examination of tissues in a transmission electron microscope (Fig. 3). There were no changes in parenchyma in rats’ livers fed with a low-fat diet (Fig. 3A). Only small droplets of lipids were found in hepatocytes. These droplets did not change the cell structure, and the hepatocytes contained all organelles. We observed a significant increase in the amount of fat droplets in hepatocyte rats fed a high-fat diet (Fig. 3B). In cytoplasm we observed numerous lipid droplets; some of them were large and merged into each other, creating cysts (Fig. 4). Inflammatory cells were found near hepatocytes (Fig. 5). Adding 1.1% GTE to the rats’ diet caused a decrease in fat content (Fig. 3C). Small lipid droplets were still seen, but they were not as large as in the case of rats fed a HF diet. Adding 2.0% GTE to the diet caused an even greater decrease in the amount of lipid droplets in cytoplasm of hepatocytes (Fig. 3D). Only sporadic droplets were found, and they did not change the distribution of cell organelles.


Hepatic steatosis evolves as a result of disorders of metabolic pathways in an organism. An increase in the amount of circulating free fatty acids appears to be the main stimulus in the pathogenesis of hepatic steatosis. In this process a very important role of various transcription factors, the effect of adipokines, disorganisation of hepatic fat oxidation, and low-density lipoprotein (VLDL) emission was found [15]. Non-treated hepatic steatosis develops into NASH, which is a chronic liver disease with high inflammatory activity, hepatocyte ballooning, the presence of Mallory’s bodies, and sometimes fibrosis [16, 17]. The progression of NASH is best described using the “two-hit theory”. According to this theory the first hit in the development of NASH is accumulation in liver excessive fat. The second hit is connected with cytokine and oxidative stress (OS), which leads to liver inflammation and fibrosis, which is the starting point in the development of NAFLD [18]. There is no efficient pharmacological therapy for NASH, so only physical activity and diet can help to reduce excessive fat accumulation in the liver.
Green tea is made from leaves of Camilia sinensis (family Theaceae). It contains polyphenols, the most important of which are the catechins: EGCG, EGC, ECG, and EC [11]. Many of the beneficial effects of green tea are assigned to EGCG, which has antioxidant, antihypertensive, anticarcinogenic, and hypercholesterolaemic effects [19, 20].
Our results indicate that supplementation of GTE reflecting habitual consumption of 5-8 cups of this beverage per day successfully reduced the amount of fat in the livers of rats during high-fat feeding. A high-fat diet triggers macrovesicular steatosis; however, adding GTE at 1.1% and 2.0% to the diet protects the liver against excessive fat accumulation in hepatocytes, development of hepatic steatosis, and further diseases connected with unnecessary lipid content in liver cells. A higher percentage of GTE in the diet caused an even more effective decrease in lipid droplets in hepatocytes. This is in agreement with studies by Nakamoto et al. [18]. They observed severe liver atrophy in NASH livers of rats. Histopathological examinations of livers showed hepatic macrovesicular steatosis, which was observed also in our semithin sections. In studies by Nakamoto et al. NASH was attenuated in all rats treated with fermented GTE [18], which was also noticed in our study after administration of 1.1% and 2.0% of regular GTE to all groups of rats fed the HF diet. However, one of the striking differences between the Nakamoto study and our present study was the content of EGCG. Nakamoto explained that only small amounts of EGCG were detected by HPLC analysis because of their decrease during the fermentation process. Therefore, it was suggested that fermented GTE prevents NASH progression through mechanism(s) different to those of EGCG. Due to abundant content, it seems that in our study EGCG in particular prevents steatohepatitis induced by a HF diet. Also, Kuzu et al. observed that EGCG in a high dose (1 g/l EGCG in drinking water) reduces the development of experimental NASH induced by a high-fat diet [21].
Other studies [22] demonstrated that obese (ob/ob) mice had severe macrovesicular steatosis and moderate inflammation. In contrast, very little steatosis and inflammation were seen in lean mice. Obese mice fed 1% GTE had reduced liver steatosis (0% GTE and 0.5% GTE in the diet had no effect on reduction of fat content in hepatocytes). Similar studies showed that GTE has a beneficial effect on leptin-deficient spontaneously obese mice [23]; it provided evidence that dietary supplementation of GTE protects against the development of hepatic steatosis and injury in obese (ob/ob) mice. Feeding with GTE at 1% and 2% reduced macrovesicular hepatic steatosis. GTE and EGCG have also been shown to inhibit fatty liver disease in mice fed a high-fat diet [24]. Our results, as well as the data in literature, suggest that only a level of GTE greater than 1% can attenuate hepatic steatosis. Lower levels of GTE (0.5%) do not prevent hepatic steatosis but can reduce the risk of hepatic injury and increase antioxidant activity in the liver [12]. Indeed, given the generally low oral bioavailability and rapid elimination of catechins, the benefits of green tea may only occur when consumed frequently (5-10 cups/day), as suggested by epidemiological studies [7].
Green tea activity consisting of lowering excessive fat accumulation in the liver is the starting point to reduce weight loss and obesity in experimental animals and also in humans. It is well known that GTE has an anti-obesity effect in humans [25, 26]. Drinking GT caused a decrease in levels of total plasma triglycerides and cholesterol in rats, it also reduced fat and starch absorption [27, 28, 29]. It was shown that consumption of water with extract of GT caused decreased body fat accumulation [30]. Studies by Murase et al. [31] showed that supplementation with GTE dose-dependently reduced body weight, adipose tissue mass, and accumulation of fat in the liver.
The effect of GTE on liver steatosis and body fat accumulation, as well as its anti-obesity action, is connected with the action of green tea catechins on lipid metabolism [32]. GTE reduced accumulation lipids in the liver by decreasing expression of adipose lipogenic genes and serum-free fatty acids. It also led to improved antioxidant activity in the liver and decreased levels of expression of tumour necrosis factor α. GTE can also downregulate proinflammatory events, which unimpeded can trigger oxidative and nitritative damage and cause NASH. GTE can reduce NADPH oxidase activity and expression of ROS. Thereby, GTE suppresses oxidative and nitritative damage that causes liver injury and NASH [33].
Although a lot of examples of the beneficial action of green tea exist in the literature, there are also reports about hepatotoxicity of GTE. If EGCG is administered at excessively high levels (750 mg/kg body weight of mice; more than 2% GTE), it can cause liver injury because of supraphysiological intake of green tea catechins [34]. Inoue et al. [35] have indicated that 1.0% green tea polyphenols disrupts kidney function through increased thiobarbituric acid-reactive substances (a reliable marker of oxidative damage) as well as down-regulation of antioxidant enzymes and heat-shock proteins in mice with dextran sodium sulphate-induced colitis, but also in normal mice, so it seems that a limitation of our study was that we failed to take into consideration a group of rats fed a normal (low-fat) diet enriched with GTE.
In the case of humans, the incidence of sporadic adverse events after consumption of large amounts of highly concentrated GTE are also available. Among such risks are the possibility of liver damage, the potential to interact with prescription drugs to alter their therapeutic efficacy, and the chance to cause harm when combined with other highly popular herbal remedies [36]. However, Donovan et al. reported that administration of decaffeinated green tea extract at a daily dose of 504 mg EGCG for 14 days did not alter CYP2D6 or 3A4 activity in healthy individuals [37]. According to Imai et al. this amount of EGCG may be anticipated with consumption of 10 or more cups of green tea per day [38].
Supplements of green tea contain much higher catechin and caffeine doses than green tea beverages. One capsule has been reported to be equal to 5-7 cups of tea. Theses capsules are usually taken more than once a day [39]. These data suggest that even when using herbs in the diet, it is recommended that the safe upper limit of its doses be identified.


The enrichment of a high-fat diet (representing a Western diet rich in animal fat) with GTE may prevent the development of dietary induced liver steatosis. Although our study was conducted on an animal model, these findings could be extrapolated to be directly applied to the human diet because the doses of GTE used in this study were equivalent to human intake of five and eight cups of green tea daily, which is approximately the amount of green tea consumed in many regions of the world [9]. In view of the increasing incidence of overweight and obesity, metabolic syndrome, and excessive energy and fat consumption, simple and cheap dietary modifications potentially influencing pathological processes may gain significance.

The study was supported by grants from Poznan University of Medical Sciences.
The authors declare no conflict of interest.


1. Schwartz MW, Seeley RJ, Zeltser LM, et al. Obesity pathogenesis: an endocrine society scientific statement. Endocr Rev 2017; 38: 267-296.
2. Romieu I, Dossus L, Barquera S, et al. Energy balance and obesity: what are the main drivers? Cancer Causes Control 2017; 28: 247-258.
3. Hill JO, Wyatt HR, Peters JC. Energy balance and obesity. Circulation 2012; 126: 126-132.
4. Rains TM, Agarwal S, Maki KC. Antiobesity effects of green tea catechins: a mechanistic review. J Nutr Biochem 2011; 22: 1-7.
5. Daskalopoulou SS, Mikhailidis DP, Elisaf M. Prevention and treatment of the metabolic syndrome. Angiology 2004; 55: 589-612.
6. Derra A, Bator M, Men¿yk T, et al. Underrated enemy – from nonalcoholic fatty liver disease to cancers of the gastrointestinal tract. Clin Exp Hepatol 2018; 4: 55-71.
7. Masterjohn C, Bruno RS. Therapeutic potential of green tea in nonalcoholic fatty liver disease. Nutr Rev 2012; 70: 41-56.
8. Wang Y, Ho CT. Polyphenolic chemistry of tea and coffee: a century of progress. J Agric Food Chem 2009; 57: 8109-8114.
9. Imai K, Nakachi K. Cross sectional study of effects of drinking green tea on cardiovascular and liver diseases. BMJ 1995; 310: 693-696.
10. Hernández Figueroa TT, Rodríguez-Rodríguez E, Sánchez-Muniz FJ. The green tea, a good choice for cardiovascular disease prevention? Arch Latinoam Nutr 2004; 54: 380-394.
11. Lambert JD, Yang CS. Mechanisms of cancer prevention by tea constituents. J Nutr 2003; 133: 3262S-3267S.
12. Park HJ, DiNatale DA, Chung MY, et al. Green tea extract attenuates hepatic steatosis by decreasing adipose lipogenesis and enhancing hepatic antioxidant defenses in ob/ob mice. J Nutr Biochem 2011; 22: 393-400.
13. Mansour-Ghanaei F, Hadi A, Pourmasoumi M, et al. Green tea as a safe alternative approach for nonalcoholic fatty liver treatment: A systematic review and meta-analysis of clinical trials: Green Tea and NAFLD. Phytother Res 2018; 32: 1876-1884.
14. Gramza-Michalowska A, Regula J. Use of tea extracts (Camelia sinensis) in jelly candies as polyphenols sources in human diet. Asia Pac J Clin Nutr 2007; 16 Suppl 1: 43-46.
15. Bajerska J, WoŸniewicz M, Jeszka J, et al. Green tea aqueous extract reduces visceral fat and decreases protein availability in rats fed with a high-fat diet. Nutr Res 2011; 31: 157-164.
16. Méndez-Sánchez N, Arrese M, Zamora-Valdés D, et al. Current concepts in the pathogenesis of nonalcoholic fatty liver disease. Liver Int 2007; 27: 423-433.
17. Kirpich IA, Marsano LS, McClain CJ. Gut-liver axis, nutrition, and non-alcoholic fatty liver disease. Clin Biochem 2015; 48: 923-930.
18. Nakamoto K, Takayama F, Mankura M, et al. Beneficial effects of fermented green tea extract in a rat model of non-alcoholic steatohepatitis. J Clin Biochem Nutr 2009; 44: 239-246.
19. Yousaf S, Butt MS, Suleria HA, et al. The role of green tea extract and powder in mitigating metabolic syndromes with special reference to hyperglycemia and hypercholesterolemia. Food Funct 2014; 5: 545-556.
20. Zhou Y, Tang J, Du Y, et al. The green tea polyphenol EGCG potentiates the antiproliferative activity of sunitinib in human cancer cells. Tumour Biol 2016; 37: 8555-8566.
21. Kuzu N, Bahcecioglu IH, Dagli AF, et al. Epigallocatechin gallate attenuates experimental non-alcoholic steatohepatitis induced by high fat diet. J Gastroenterol Hepatol 2008; 23: e465-470.
22. Chung MY, Park HJ, Manautou JE, et al. Green tea extract protects against nonalcoholic steatohepatitis in ob/ob mice by decreasing oxidative and nitrative stress responses induced by proinflammatory enzymes. J Nutr Biochem 2012; 23: 361-367.
23. Bruno RS, Dugan CE, Smyth JA, et al. Green tea extract protects leptin-deficient, spontaneously obese mice from hepatic steatosis and injury. J Nutr 2008; 138: 323-331.
24. Bose M, Lambert JD, Ju J, et al. The major green tea polyphenol, (-)-epigallocatechin-3-gallate, inhibits obesity, metabolic syndrome, and fatty liver disease in high-fat-fed mice. J Nutr 2008; 138: 1677-1683.
25. Maki KC, Reeves MS, Farmer M, et al. Green tea catechin consumption enhances exercise-induced abdominal fat loss in overweight and obese adults. J Nutr 2009; 139: 264-270.
26. Huang J, Wang Y, Xie Z, et al. The anti-obesity effects of green tea in human intervention and basic molecular studies. Eur J Clin Nutr 2014; 68: 1075-1087.
27. Yang MH, Wang CH, Chen HL. Green, oolong and black tea extracts modulate lipid metabolism in hyperlipidemia rats fed high-sucrose diet. J Nutr Biochem 2001; 12: 14-20.
28. Lochocka K, Bajerska J, Glapa A, et al. Green tea extract decreases starch digestion and absorption from a test meal in humans: a randomized, placebo-controlled crossover study. Sci Rep 2015; 5: 12015.
29. Walkowiak J, Bajerska J, Kargulewicz A, et al. Single dose of green tea extract decreases lipid digestion and absorption from a test meal in humans. Acta Biochim Pol 2013; 60: 481-483.
30. Choo JJ. Green tea reduces body fat accretion caused by high-fat diet in rats through beta-adrenoceptor activation of thermogenesis in brown adipose tissue. J Nutr Biochem 2003; 14: 671-676.
31. Murase T, Nagasawa A, Suzuki J, et al. Beneficial effects of tea catechins on diet-induced obesity: stimulation of lipid catabolism in the liver. Int J Obes Relat Metab Disord 2002; 26: 1459-1464.
32. Cabrera C, Artacho R, Giménez R. Beneficial effects of green tea-a review. J Am Coll Nutr 2006; 25: 79-99.
33. Higdon JV, Frei B. Tea catechins and polyphenols: health effects, metabolism, and antioxidant functions. Crit Rev Food Sci Nutr 2003; 43: 89-143.
34. Lambert JD, Kennett MJ, Sang S, et al. Hepatotoxicity of high oral dose (-)-epigallocatechin-3-gallate in mice. Food Chem Toxicol 2010; 48: 409-416.
35. Inoue H, Akiyama S, Maeda-Yamamoto M, et al. High-dose green tea polyphenols induce nephrotoxicity in dextran sulfate sodium-induced colitis mice by down-regulation of antioxidant enzymes and heat-shock protein expressions. Cell Stress Chaperones 2011; 16: 653-662.
36. Schönthal AH. Adverse effects of concentrated green tea extracts. Mol Nutr Food Res 2011; 55: 874-885.
37. Donovan JL, Chavin KD, Devane CL, et al. Green tea (Camellia sinensis) extract does not alter cytochrome p450 3A4 or 2D6 activity in healthy volunteers. Drug Metab Dispos 2004; 32: 906-908.
38. Imai K, Suga K, Nakachi K. Cancer-preventive effects of drinking green tea among a Japanese population. Prev Med 1997; 26: 769-775.
39. Inoue M, Kurahashi N, Iwasaki M, et al. Effect of coffee and green tea consumption on the risk of liver cancer: cohort analysis by hepatitis virus infection status. Cancer Epidemiol Biomark Prev 2009; 18: 1746-1753.

Address for correspondence

Jarosław Walkowiak
Department of Gastroenterology and Metabolic Diseases
Poznan University of Medical Sciences
Szpitalna 27/33
60-572 Poznan, Poland
Copyright: © 2020 Polish Association of Pathologists and the Polish Branch of the International Academy of Pathology This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Quick links
© 2022 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.